158 related articles for article (PubMed ID: 8494369)
1. In vitro antimicrobial activity of a new antibiotic, MDL 62,879 (GE2270 A).
Goldstein BP; Berti M; Ripamonti F; Resconi A; Scotti R; Denaro M
Antimicrob Agents Chemother; 1993 Apr; 37(4):741-5. PubMed ID: 8494369
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of MDL 62,879 (GE2270 A) against aerobic gram-positive and anaerobic bacteria.
King A; Bethune L; Phillips I
Antimicrob Agents Chemother; 1993 Apr; 37(4):746-9. PubMed ID: 8494370
[TBL] [Abstract][Full Text] [Related]
3. In vitro antimicrobial activity of the thiazolyl peptide antibiotic MDL 62,879 (GE2270 A).
Kenny MT; Brackman MA; Dulworth JK
Chemotherapy; 1997; 43(4):254-63. PubMed ID: 9209782
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of MDL 62,879 against gram-positive bacteria and Bacteroides species.
Bartoloni A; Mantella A; Goldstein BP; Denaro M; Nicoletti P; Paradisi F
Eur J Clin Microbiol Infect Dis; 1995 Dec; 14(12):1105-8. PubMed ID: 8681991
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
[TBL] [Abstract][Full Text] [Related]
6. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Stratford RE; Cooper RD
Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of telavancin against resistant gram-positive bacteria.
Krause KM; Renelli M; Difuntorum S; Wu TX; Debabov DV; Benton BM
Antimicrob Agents Chemother; 2008 Jul; 52(7):2647-52. PubMed ID: 18443122
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic GE2270 a: a novel inhibitor of bacterial protein synthesis. I. Isolation and characterization.
Selva E; Beretta G; Montanini N; Saddler GS; Gastaldo L; Ferrari P; Lorenzetti R; Landini P; Ripamonti F; Goldstein BP
J Antibiot (Tokyo); 1991 Jul; 44(7):693-701. PubMed ID: 1908853
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.
Biavasco F; Lupidi R; Varaldo PE
Antimicrob Agents Chemother; 1992 Feb; 36(2):331-8. PubMed ID: 1534977
[TBL] [Abstract][Full Text] [Related]
10. Glycopeptide tolerance in bacteria causing endocarditis.
Perry JD; Jones AL; Gould FK
J Antimicrob Chemother; 1999 Jul; 44(1):121-4. PubMed ID: 10459820
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.
Jamjian C; Biedenbach DJ; Jones RN
Antimicrob Agents Chemother; 1997 Feb; 41(2):454-9. PubMed ID: 9021207
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of elongation factor Tu (EF-Tu) from different bacterial species to the antibiotics efrotomycin, pulvomycin and MDL 62879.
Landini P; Bandera M; Soffientini A; Goldstein BP
J Gen Microbiol; 1993 Apr; 139(4):769-74. PubMed ID: 8515234
[TBL] [Abstract][Full Text] [Related]
13. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of A-16686, a new glycopeptide.
Neu HC; Neu NM
Chemotherapy; 1986; 32(5):453-7. PubMed ID: 3757587
[TBL] [Abstract][Full Text] [Related]
15. Antistaphylococcal and antienterococcal activity of the new teicoplanin amide derivative MDL 62873.
Qadri SM; Saldin H; Ueno Y
Chemotherapy; 1993; 39(1):55-8. PubMed ID: 8444061
[TBL] [Abstract][Full Text] [Related]
16. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
Jones RN; Low DE; Pfaller MA
Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of bacterial protein synthesis by elongation-factor-Tu-binding antibiotics MDL 62,879 and efrotomycin.
Landini P; Bandera M; Goldstein BP; Ripamonti F; Soffientini A; Islam K; Denaro M
Biochem J; 1992 May; 283 ( Pt 3)(Pt 3):649-52. PubMed ID: 1590753
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.
Goldstein BP; Candiani G; Arain TM; Romanò G; Ciciliato I; Berti M; Abbondi M; Scotti R; Mainini M; Ripamonti F
Antimicrob Agents Chemother; 1995 Jul; 39(7):1580-8. PubMed ID: 7492108
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.
Noskin GA; Siddiqui F; Stosor V; Hacek D; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2059-62. PubMed ID: 10428937
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic GE37468 A: a new inhibitor of bacterial protein synthesis. I. Isolation and characterization.
Stella S; Montanini N; Le Monnier F; Ferrari P; Colombo L; Marinelli F; Landini P; Ciciliato I; Goldstein BP; Selva E
J Antibiot (Tokyo); 1995 Aug; 48(8):780-6. PubMed ID: 7592021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
